探访欧姆龙大连工厂 “智律波”让测量血压的同时提示房颤风险

Core Viewpoint - Omron has established itself as a leader in health care devices, particularly in blood pressure monitors, and is expanding its innovative technologies to address cardiovascular risks, particularly atrial fibrillation [1][6][8]. Group 1: Company Overview - Omron established its first factory in China in 1993, making the Dalian facility the largest global production base for Omron's health care division [1]. - The company operates in four major business areas: health care, industrial automation, electronic components, and social solutions [2]. Group 2: Innovative Technology - The "Intellisense Afib" technology allows blood pressure monitors to simultaneously detect the risk of atrial fibrillation during blood pressure measurement [8]. - This technology is based on 50 years of pulse wave data and integrates AI to enhance the accuracy of atrial fibrillation detection [8]. Group 3: Market Position and Strategy - China accounts for 33% of Omron's global health care sales, highlighting its significance as a key market [6]. - The aging population and the rise of health-conscious younger generations present substantial growth opportunities for Omron's products [6]. Group 4: Product Development - The new generation blood pressure monitor, HCG-7800T, improves accuracy and ease of use, allowing for simultaneous blood pressure and atrial fibrillation detection [9]. - Omron has sold over 350 million home blood pressure monitors globally as of April 2023, indicating strong market penetration [11]. Group 5: Future Vision - Omron aims to achieve three zeros in its health care business: zero occurrences of cardiovascular events, zero deterioration of respiratory diseases, and zero limitations in daily life due to chronic pain [14].